Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting

Reuters

2025/07/24

Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting

Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis $(PFI.NZ)$ and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum $(CCH.UK)$ for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553781207"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553781207\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553781207?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553781207","market":"fut","top_or_hot":-1,"title":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis <a href=\"https://laohu8.com/S/PFI.NZ\">$(PFI.NZ)$</a> and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum <a href=\"https://laohu8.com/S/CCH.UK\">$(CCH.UK)$</a> for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEndo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-24 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis <a href=\"https://laohu8.com/S/PFI.NZ\">$(PFI.NZ)$</a> and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum <a href=\"https://laohu8.com/S/CCH.UK\">$(CCH.UK)$</a> for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL8sYHHZ:1","article_id":"2553781207","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553781207","pubTimestamp":1753356635,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting. Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis  and plantar fasciitis  at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum  for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NDOI":"Endo, Inc."},"translate_title":"Endo Inc.在美国足病医学协会会议上宣布非手术治疗足底纤维瘤病的3期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDOI":0.9},"content_text":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n    \n\n        Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis $(PFI.NZ)$ and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum $(CCH.UK)$ for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}